Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Regulatory News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Interim Results

27 Jul 2017 07:00

RNS Number : 2146M
Vectura Group plc
27 July 2017
 

Vectura Group plc

Notice of Interim Results

Chippenham, UK, 27 July 2017: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading inhaled airways disease focused business, plans to announce its Interim Results for the six-month period ending 30 June 2017 on Wednesday 6 September 2017.

James Ward-Lilley, Chief Executive Officer, and Andrew Derodra, Chief Financial Officer, will host a briefing for analysts at 9.30am on the morning of the results at the offices of Numis Securities Ltd., 10 Paternoster Square, London, EC4M 7LT.

A live webcast of the meeting, with the presentation slides, will be available on Vectura's website: http://www.vectura.com/investors/presentations-webcasts/.

- ENDS -

 

 

For more information, please contact:

 

Vectura Group plc

+44 (0)1249 667700

Andrew Derodra - Chief Financial Officer

Fleur Wood - Director Communications

Elizabeth Knowles - Director Investor Relations and Analysis

 

 

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart / Jessica Hodgson

 vectura@consilium-comms.com

 

 

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. 

 

Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOROKADKOBKDQOB
Date   Source Headline
17th Aug 20213:41 pmBUSForm 8.3 - Vectura Group plc
17th Aug 20213:20 pmRNSForm 8.3 - Vectura Group plc
17th Aug 20212:45 pmRNSForm 8.3 - Vectura Group plc
17th Aug 20212:36 pmRNSForm 8.3 - Vectura Plc
17th Aug 20211:12 pmEQSForm 8.3 - The Vanguard Group, Inc.: Vectura Group plc
17th Aug 202112:32 pmRNSForm 8.3 - Vectura Group plc
17th Aug 202112:06 pmRNSForm 8.3 - Vectura Group plc
17th Aug 202111:55 amRNSForm 8.5 (EPT/NON-RI)- Vectura Group plc
17th Aug 202111:52 amRNSForm 8.5 (EPT/RI)- Vectura Group plc
17th Aug 202111:48 amRNSForm 8.5 (EPT/RI)
17th Aug 202111:06 amRNSForm 8.5 (EPT/RI) - VECTURA GROUP PLC
17th Aug 202111:02 amRNSHolding(s) in Company
17th Aug 202110:58 amBUSForm 8.3 - VECTURA GROUP PLC
17th Aug 202110:02 amRNSForm 8.3 - Vectura Group Plc
16th Aug 20215:45 pmRNSPublication and posting of Offer Document
16th Aug 20213:30 pmRNSForm 8.3 - VEC LN
16th Aug 20213:30 pmBUSForm 8.3 - Vectura Group plc
16th Aug 20213:20 pmRNSForm 8.3 - Vectura Group plc
16th Aug 202112:33 pmRNSForm 8.3 - Vectura Group plc
16th Aug 202111:40 amRNSForm 8.5 (EPT/RI)
16th Aug 202111:38 amRNSForm 8.5 (EPT/NON-RI)
16th Aug 202111:38 amBUSForm 8.3 - VECTURA GROUP PLC
16th Aug 202111:18 amRNSForm 8.5 (EPT/NON-RI)- Vectura Group plc
16th Aug 202111:10 amRNSForm 8.5 (EPT/RI)- Vectura Group plc
16th Aug 202110:59 amRNSForm 8.5 (EPT/RI) - VECTURA GROUP PLC
16th Aug 202110:41 amRNSForm 8.3 - Vectura Group Plc
16th Aug 20217:00 amRNSHolding(s) in Company
13th Aug 20214:35 pmRNSForm 8.5 (EPT/RI) - Replacement of VECTURA GROUP
13th Aug 20213:20 pmRNSForm 8.3 - Vectura Group plc
13th Aug 20213:15 pmRNSForm 8.3 - Vectura Group Plc
13th Aug 20213:15 pmBUSForm 8.3 - Vectura Group plc
13th Aug 20213:09 pmRNSForm 8.3 - Vectura Group Plc
13th Aug 202111:35 amRNSForm 8.5 (EPT/RI)- Vectura Group plc
13th Aug 202111:32 amBUSForm 8.3 - VECTURA GROUP PLC
13th Aug 202111:21 amRNSForm 8.5 (EPT/RI)
13th Aug 202110:05 amRNSForm 8.5 (EPT/RI) - VECTURA GROUP PLC
13th Aug 202110:02 amRNSForm 8.3 - Vectura Group Plc
13th Aug 20219:58 amRNSForm 8.3 - Vectura Group plc
12th Aug 20215:01 pmRNSStatement re final offers for Vectura Group plc
12th Aug 20214:30 pmRNSForm 8.5 (EPT/RI)- Vectura Group plc Amnd
12th Aug 20214:29 pmRNSForm 8.5 (EPT/RI)- Vectura Group plc Amnd
12th Aug 20214:03 pmRNSForm 8.5 (EPT/RI)-Replacement of VECTURA GROUP PLC
12th Aug 20213:59 pmRNSForm 8.5 (EPT/RI)-Replacement of VECTURA GROUP PLC
12th Aug 20213:15 pmBUSForm 8.3 - Vectura Group plc
12th Aug 20213:06 pmRNSForm 8.3 - Vectura Group Plc
12th Aug 20212:33 pmEQSForm 8.3 - The Vanguard Group, Inc.: Vectura Group plc
12th Aug 20212:17 pmRNSForm 8.3 - Vectura Group plc
12th Aug 202111:48 amRNSForm 8.5 (EPT/RI)
12th Aug 202111:47 amRNSForm 8.5 (EPT/NON-RI)
12th Aug 202111:30 amRNSForm 8.5 (EPT/RI) - VECTURA GROUP PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.